Fister Stefanie, Günthert Andreas R, Aicher Babette, Paulini Klaus W, Emons Günter, Gründker Carsten
Department of Gynecology and Obstetrics, Georg-August-University, Göttingen, Germany.
Cancer Res. 2009 Aug 15;69(16):6473-81. doi: 10.1158/0008-5472.CAN-08-4657. Epub 2009 Jul 28.
Recently, we could show that gonadotropin-releasing hormone (GnRH)-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells in vitro and in vivo. In the present study, we have ascertained receptor binding and effects of GnRH-II antagonists on mitogenic signal transduction and on activation of proapoptotic protein Bax. The GnRH-II antagonists tested showed EC50 values for GnRH-I receptor binding in the range of 1 to 2 nmol/L. The GnRH-II agonist [D-Lys6]GnRH-II showed an EC50 value for GnRH-I receptor binding of approximately 1,000 nmol/L. Agonistic activity on GnRH-I receptor function with an EC50 of 13 nmol/L has been determined for [D-Lys6]GnRH-II. Antagonistic activities with EC50 values in the range of 1 nmol/L were determined for the GnRH-II antagonists. Treatment of human endometrial, ovarian, and breast cancer cells with GnRH-II antagonists resulted in time-dependent activation of stress-induced mitogen-activated protein kinases p38 and c-Jun NH2-terminal kinase. In addition, treatment with GnRH-II antagonists induced time-dependent activation of proapoptotic protein Bax. GnRH-II antagonists are not involved in activation of protein kinase B/Akt or extracellular signal-regulated kinase 1/2. The GnRH-II antagonists tested had similar binding affinities to the GnRH-I receptor comparable with that of GnRH-I antagonist Cetrorelix. Referring to the cyclic AMP response element reporter gene activation assay, the GnRH-II agonist [D-Lys6]GnRH-II has to be classified as an agonist at the GnRH-I receptor, whereas the GnRH-II antagonists tested are clear antagonists at the GnRH-I receptor. GnRH-II antagonists induce apoptotic cell death in human endometrial, ovarian, and breast cancer cells via activation of stress-induced mitogen-activated protein kinases p38 and c-Jun NH2-terminal kinase followed by activation of proapoptotic protein Bax.
最近,我们能够证明促性腺激素释放激素(GnRH)-II拮抗剂在体外和体内均可诱导人子宫内膜癌、卵巢癌和乳腺癌细胞凋亡。在本研究中,我们确定了GnRH-II拮抗剂的受体结合情况及其对促有丝分裂信号转导和促凋亡蛋白Bax激活的影响。所测试的GnRH-II拮抗剂对GnRH-I受体结合的EC50值在1至2 nmol/L范围内。GnRH-II激动剂[D-Lys6]GnRH-II对GnRH-I受体结合的EC50值约为1000 nmol/L。已确定[D-Lys6]GnRH-II对GnRH-I受体功能具有激动活性,EC50为13 nmol/L。所测试的GnRH-II拮抗剂的拮抗活性的EC50值在1 nmol/L范围内。用GnRH-II拮抗剂处理人子宫内膜癌、卵巢癌和乳腺癌细胞会导致应激诱导的丝裂原活化蛋白激酶p38和c-Jun氨基末端激酶的时间依赖性激活。此外,用GnRH-II拮抗剂处理会诱导促凋亡蛋白Bax的时间依赖性激活。GnRH-II拮抗剂不参与蛋白激酶B/Akt或细胞外信号调节激酶1/2的激活。所测试的GnRH-II拮抗剂与GnRH-I拮抗剂西曲瑞克相比,对GnRH-I受体具有相似的结合亲和力。参照环磷酸腺苷反应元件报告基因激活试验,GnRH-II激动剂[D-Lys6]GnRH-II在GnRH-I受体上应归类为激动剂,而所测试的GnRH-II拮抗剂在GnRH-I受体上则为明确的拮抗剂。GnRH-II拮抗剂通过激活应激诱导的丝裂原活化蛋白激酶p38和c-Jun氨基末端激酶,随后激活促凋亡蛋白Bax,从而诱导人子宫内膜癌、卵巢癌和乳腺癌细胞发生凋亡性细胞死亡。